biological research within our laboratories . Once the In-Orbit Demonstration Pilot mission reaches its conclusion , our StarLab will have the necessary space qualification to facilitate numerous extended-duration biological experiments in space .
What are your long-term vision for space tech development vis a vis various segments of the bioscience sector ? futuristic space tech market ?
Our core aim is to offer economical and scalable options for the Indian Bioscience and Semiconductor sectors , leveraging our StarLab platform . Through small microgravity experiments , we seek to broaden access to space , catalyzing a shift from space R & D to In-Space Manufacturing . Vellon Space ' s collective mission is to introduce Industries to perform groundbreaking discoveries like new medications , artificial organs , and space-cultivated protein crystals , benefiting both industries and life on Earth . By 2030 , Vellon Space aims to build a space-based manufacturing platform . This platform offers a distinctive environment that fosters research and facilitates product commercialization , contributing to a more environmentally-friendly Earth
What is your business model and how is the company funded currently ?
We provide space-as-a-service for the industries looking for advancing their technology through microgravity and long duration space access . The company also focuses on providing the meta data bioinformatics to the earthen
By incorporating cutting-edge microfluidics technology , we are able to shrink a wide array of experiments .
industries for rapid disease studies and drug manufacturing .
Our company is currently self-funded , but we are gearing up for our upcoming seed round of investments . By next year , we will have successfully completed our in-orbit demonstration and achieved space qualification for StarLab , a cutting-edge platform for bio-manufacturing research .
Financial performance and revenue expectations in the next few years ?
Our strategic vision entails a transformative impact by 2030 . We project that our services will enable the launch of approximately 600 kilograms of bio-manufacturing and multisector experiments into space . Furthermore , we aim to capture a significant 15 % share of the global bio-manufacturing industries market . In the years ahead , we anticipate a 30 % increase in the biomanufacturing sector as we leverage our state-of-the-art space laboratories for activities such as drug manufacturing , artificial organ creation , and more . Our strategic approach not only embraces innovation but also fosters profound advancements in various industries .
BioTech
BIOVOICENEWS . COM 59